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OBJECTIVES: Cost-effectiveness of denosumab versus oral bisphosphonates in 
MOP was evaluated from a third-party payer perspective in Sweden. METHODS: 
A lifetime cohort Markov model was developed to reflect osteoporotic health 
states. During each cycle, patients could have a fracture, remain healthy, remain 
in a post fracture state or die. Background fracture risks, mortality rates, 
persistence rates, utilities, medical and drug costs were derived using published 
sources. Bone mineral density (BMD) improvements have been shown to be 
similar between MOP and post-menopausal osteoporotic (PMO) populations, and 
a recent fracture trial showed zoledronate to have effects in men similar to those 
reported previously in women; therefore efficacy data from PMO women were 
used. Lifetime expected costs and quality-adjusted life-years (QALYs) were 
estimated for denosumab, generic alendronate, generic risedronate, and 
ibandronate. Patients in the model were 65-year-old men, with BMD T-score≤-
1.90 and prevalent vertebral fracture of 22.7%. In the base-case, the model 
assumed patients could receive treatment effects up to 2 years after 
discontinuation (offset time). Costs and QALYs were discounted at 3% annually. 
Extensive sensitivity analyses were conducted. RESULTS: Total lifetime costs for 
alendronate, denosumab, risedronate, and ibandronate were €45,118, €45,396, 
€45,526, and €46,523, respectively. Total QALYs were 9.86, 9.91, 9.85, and 9.83, 
respectively. Denosumab had an incremental cost-effectiveness ratio (ICER) of 
€5,283 compared to alendronate and dominated risedronate and ibandronate. 
Results were most sensitive to changes in relative risk (RR) of hip fracture with 
denosumab, cost of denosumab and RR of vertebral fracture with denosumab. 
The probability of denosumab being cost-effective compared to oral 
bisphosphonates at a threshold of €66,000/QALY was 85.5%. In a sensitivity 
analysis of offset time of 5 years for oral bisphosphonates, denosumab had an 
ICER of €10,382 compared to alendronate. CONCLUSIONS: Denosumab is cost-
effective compared to branded and generic oral bisphosphonates in the Swedish 
MOP population.  
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OBJECTIVES: Rheumatoid arthritis (RA) guidelines say little regarding optimal 
treatment after first-line biologics. We applied a published claims-based 
algorithm to estimate treatment effectiveness (as a proxy for low disease activity 
or remission) and cost per responder in US managed care patients with RA who 
switched to a new biologic after previously initiating etanercept, adalimumab, 
infliximab, golimumab, or abatacept, for first-line treatment of moderate to 
severe RA. METHODS: Data were obtained from IMS PharMetrics Plus™, which 
comprises adjudicated medical and pharmaceutical claims for 150 million 
enrollees (40 million annually). An initial cohort included patients with RA aged 
18-63, initiating biologic treatment 2007-2010, without diagnoses for other 
approved indications for these biologics, without any biologic use in the 6 
months before initiation, and enrolled 12 months after initiation. The subset of 
patients who switched to a second biologic within 1 year of initiation (and before 
3/21/2011) and were enrolled an additional year after switching, and had ≥100 
patients were eligible for this analysis. The algorithm defined lack of 
effectiveness as: medication possession ratio (MPR) <80% (or fewer infusions 
than specified on US label), increase in biologic dose or frequency, switching 
biologics, adding new non-biologic Disease Modifying Anti-Rheumatic Drugs, 
initiation or increase of glucocorticoid dose, or >1 parenteral or intra-articular 
injection. RESULTS: Of 16,011 initial cohort patients, 1,243 met criteria for this 
analysis and switched to: etanercept (n=318), adalimumab (n=527), infliximab 
(n=202), and abatacept (n=196). Mean age at switch was 48.9 (SD 9.9), 80.2% were 
female. Post-switch biologics met algorithm critiera for “effective” in 22% of 
etanercept, 11% of infliximab, 21% of adalimumab, and 25% of abatacept 
patients. Cost per responder was $64,449 for etanercept, $226,167 for infliximab, 
$71,877 for adalimumab, and $87,563 for abatacept. CONCLUSIONS: Although 
abatacept was more effective second line than the other agents, the cost per 
responder was lower for etanercept and adalimumab.  
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OBJECTIVES: A recently published claims-based algorithm to evaluate effectiveness 
of biologics for rheumatoid arthritis (RA) was validated using data from the Veteran 
Health Administration and VA RA registry. The objective was to compare 1-year 
cost per responder among biologics approved for first-line treatment of moderate to 
severe RA, etanercept, adalimumab, infliximab, golimumab, and abatacept among 
patients in a US health plan using this claims-based algorithm. METHODS: This 
retrospective cohort study used commercial claims data from the Optum Research 
Database, including medical and pharmacy claims for >13.3 million individuals. 
Adult patients with RA (ICD-9 714.0x) newly initiating biologic treatment between 
Jan 1, 2008 and Dec 1, 2010 followed by ≥12 months of continuous enrollment were 
included. Patients with other diagnoses for which these agents are approved were 
excluded. The algorithm classifies a drug as “non-effective” if any of the following 
criteria are met: low adherence MPR < 80% or receiving less than the expected 
number of infusions/injections; increase in biologic dose or frequency; switching 
biologics; adding new non-biologic Diseases Modifying Anti-Rheumatic Drugs; new 
glucocorticoid use or increase in glucocorticoid dose; and > 1 parenteral or intra-
articular glucocorticoid injection. Drug costs were estimated using actual 
medication usage and administration costs. Non-responders were defined as 
patients in whom the drug was classified as “non-effective”. RESULTS: A total of 
5,474 patients (2,425 etanercept, 1,857 adalimumab, 773 infliximab, 295 abatacept, 
and 124 golimumab) were included. Across agents, between 76% and 85% were 
female, with a mean age of 48 years. The medications were classified “effective” 
(low disease activity or remission) in 32.7%, 27.7%, 19.0%, 30.2%, and 32.3% of 
patients respectively. Mean cost per responder was lowest for etanercept ($43,935), 
followed by golimumab ($49,589), adalimumab ($52,752), abatacept ($62,300), and 
infliximab ($101,402). CONCLUSIONS: Etanercept had the lowest cost per responder 
in RA using a new, validated claims based algorithm.  
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OBJECTIVES: To estimate the cost-effectiveness of abatacept in combination 
with methotrexate (MTX) versus rituximab or tocilizumab in combination with 
MTX, in patients with Rheumatoid Arthritis with inadequate response to 
methotrexate (IR-MTX) in Chile. METHODS: Adapting a previously validated 
model, dynamic simulation techniques and clinical data from published 
literature were used to compare the clinical events, quality of life, and direct 
medical costs of abatacept, rituximab and tocilizumab. Costs of drug acquisition, 
administration and monitoring were considered. Costs were expressed in US 
Dollars of 2012 (Exchange rate: $ 487.8 Chilean pesos=1 US Dollar). A 5-year time 
horizon for a cohort of 1000 patients and the payer’s perspective were assumed. 
Costs and health outcomes were discounted at 6% annually. Univariate 
sensitivity analysis was performed to assess the robustness of the model results. 
RESULTS: A hypothetical cohort of 1,000 patients with RA and IR-MTX in Chile, 
followed for 5 years, resulted in mean drug costs of: US$40,792, US$21,952, and 
US$35,849, for abatacept, rituximab and tocilizumab, respectively. Total direct 
medical costs (discounted) per patient were US$47,533 (46,510-48,848) for 
abatacept, US$27,428 (27,017-27,914) for rituximab, and US$ 42,543 (41,545- 
44,428) for tocilizumab. The total QALYs gained (discounted) by abatacept, 
rituximab and tocilizumab during the same period were: 2.06 (2.01-2.10), 1.11 
(1.07-1.16) and 1.93 (1.87-1.97) respectively. The calculated Incremental Cost-
Effectiveness Ratio (ICER) for abatacept compared to rituximab and tocilizumab 
were US$21,117 (18,089-25,792) and US$37,614 (9,179-185,253) per QALY gained, 
respectively. Sensitivity analysis confirmed the robustness of the model findings. 
CONCLUSIONS: In Chile, according to the model inputs, abatacept showed better 
effectiveness in terms of QALYs than rituximab or tocilizumab, for patients with 
rheumatoid arthritis after an inadequate response to MTX. The results suggest 
that abatacept is cost-effective compared to rituximab (ICER ≤3 GDP per capita).  
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OBJECTIVES: To estimate the cost-effectiveness of Abatacept in combination 
with methotrexate (MTX) versus infliximab or tocilizumab in combination with 
MTX, in patients with rheumatoid arthritis with inadequate response to 
methotrexate (IR-MTX) in Argentina. METHODS: Adapting a previously validated 
model, dynamic simulation techniques and clinical data from published 
literature were used to compare the clinical events, quality of life, and direct 
medical costs of abatacept, infliximab and tocilizumab. Costs of drug acquisition, 
administration and monitoring were considered. Costs were calculated from 
social security system of Argentina (Exchange rate: $4.41 Argentinean pesos=1 
US Dollar). A 5-year time horizon was assumed. Costs and health outcomes were 
discounted at 3% annually. Univariate sensitivity analysis was performed to 
assess the robustness of the results of the model. RESULTS: A hypothetical 
cohort of 1,000 patients with RA and IR MTX in Argentina, followed for 5 years, 
resulted in mean drug costs of: US$70,427, US$80,930, and US$85,986, for 
abatacept, infliximab and tocilizumab, respectively. Total direct medical costs 
(discounted) per patient were US$78,458 (76,543-81,290) for abatacept, US$ 89,752 
(87,705-95,250) for infliximab, and US$ 93,492 (90,916-98,903) for tocilizumab. The 
total QALYs gained (discounted) by abatacept, infliximab and tocilizumab during 
the same period were: 2.47 (2.41-2.50), 2.39 (2.34-2.43) and 2.39 (2.34-2.43) 
respectively. Using abatacept as the reference treatment, infliximab and 
tocilizumab provided less utility at a higher cost, being dominated by abatacept. 
